From International Journal of Radiation Oncology, August 16, 2 022
In this review, the authors outline the evidence to date from clinical trials assessing the utility of radiotherapy in patients with oligometastatic prostate cancer. Primary prostate radiation in the de novo metastatic setting prolongs biochemical progression–free survival (BPFS) and may provide a survival benefit in patients with less than five bone metastases. Metastasis-directed therapy in the form of stereotactic ablative body radiotherapy (SABR) may provide benefits beyond local control in both patients with hormone-sensitive and hormone-resistant prostate cancer, including longer BPFS and radiologic PFS.
Radiotherapy, particularly SABR, should be considered in patients with oligometastatic prostate cancer. Highly-sensitive imaging modalities, such as PSMA PET, are essential to identify patients most likely to benefit from radiotherapy.
– Charles Gaulin, MBBS